Bullfrog AI Holdings, Inc. Warrants - BFRGW STOCK NEWS

BullFrog AI Holdings, Inc. (NASDAQ: BFRG) has announced significant progress in its collaboration with the Lieber Institute for Brain Development (LIBD) to uncover new insights into bipolar disorder (BD) pathways and potential drug targets. The research has identified specific molecular pathways associated with BD, enabling the discovery of new candidate drug targets.

Key findings include:

• Significant enrichment in 6 out of 68 clusters from the LIBD brain dataset
• Two substantially enriched clusters in the Dentate Gyrus
• One specific cluster associated with BD in the Dorsolateral Prefrontal Cortex
• Potential dysregulation of pro-inflammatory pathways
• Identification of novel pathways significant to BD pathophysiology

BullFrog AI is now focusing on validating these findings in wet lab settings and engaging with pharmaceutical partners to advance these discoveries.

BullFrog AI (NASDAQ: BFRG) is hosting a live investor webinar on June 12, 2024, at 4:15 p.m. ET, featuring insights from CSO Tom Chittenden and LIBD CEO Daniel Weinberger on their collaborative research. The study, using over 2,800 brain samples, has revealed novel insights into psychiatric conditions such as schizophrenia and bipolar disorder through advanced AI techniques. This collaboration has enabled clustering based on biological data, uncovering potential biomarkers and drug targets. The event aims to provide comprehensive details on these findings and discuss future revenue opportunities through potential pharmaceutical partnerships.

BullFrog AI and the Lieber Institute for Brain Development (LIBD) announced significant progress in their collaboration to identify novel drug targets for neuropsychiatric disorders. Using AI and machine learning, they have discovered patient subgroups within conditions like major depression, schizophrenia, and bipolar disorder. This approach led to identifying key genes that present new potential drug targets. BullFrog AI is applying Causal AI to validate these targets, aiming to develop targeted treatments for psychiatric disorders. The collaboration has also started engagements with pharmaceutical companies for strategic partnerships.

BullFrog AI Holdings, Inc. announces Chief Scientific Officer's presentation on Quantum Assisted AI/ML for Precision Medicine at Bio-IT World Conference & Expo. The presentation focuses on using quantum methods to analyze disease patterns, including multi-omics cancer data and severe COVID-19 patient classification, showcasing the potential of quantum computing in revolutionizing precision medicine.

BullFrog AI Holdings, Inc. announces the availability of a fireside chat recording featuring CEO Vin Singh and Dr. Daniel Weinberger. The collaboration with Lieber Institute for Brain Development explores psychiatric conditions using advanced graph analytics on 2,800 brain samples, revealing potential biological subtypes within disorders.

BullFrog AI Holdings, Inc. appoints Dr. Thomas W. Chittenden as Chief Scientific Officer, bringing extensive experience in AI, machine learning, and drug discovery. Dr. Chittenden's leadership is expected to drive innovation in drug development and accelerate BullFrog AI's mission.

BullFrog AI Holdings, Inc. announces the Underwriter's decision to exercise their over-allotment option to purchase 218,382 shares of the Company's common stock. The offering was made via a prospectus filed with the SEC and facilitated by WallachBeth Capital, LLC.

BullFrog AI Holdings, Inc. announces a fireside chat with CEO Vin Singh and Dr. Daniel R. Weinberger to discuss groundbreaking collaboration with LIBD on psychiatric research using AI and machine learning. The partnership aims to provide new insights into brain disorders and potential treatments.

WallachBeth Capital LLC announced that BullFrog AI Holdings, Inc. has completed an underwritten public offering, raising approximately $5.7 million. The company offered 1,507,139 shares of common stock at a public offering price of $3.782 per share. Additionally, the underwriters have a 45-day option to purchase an additional 226,071 shares to cover over-allotments. The offering was managed by WallachBeth Capital, LLC.